

UNCLASSIFIED

AD NUMBER
ADB261617
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; May 2000. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott St., Fort Detrick, MD 21702-5012.
AUTHORITY
USAMRMC ltr, dtd 21 Feb 2003

THIS PAGE IS UNCLASSIFIED

AD _____

Award Number: DAMD17-99-1-9308

TITLE: Differential Activation of p53 Target Genes in Breast
Cancer

PRINCIPAL INVESTIGATOR: Edward Thornborrow, MA
James Manfredi, Ph.D.

CONTRACTING ORGANIZATION: Mount Sinai School of Medicine
New York, New York 10029

REPORT DATE: June 2000

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government
agencies only (proprietary information, May 00). Other requests
for this document shall be referred to U.S. Army Medical Research
and Materiel Command, 504 Scott Street, Fort Detrick, Maryland
21702-5012.

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

20010110 038

DTIC QUALITY INSPECTED 3

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-99-1-9308

Organization: Mount Sinai School of Medicine

Location of Limited Rights Data (Pages):

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

Kath Mone 11/29/00

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE June 2000	3. REPORT TYPE AND DATES COVERED Annual Summary (1 May 99 - 1 May 00)	
4. TITLE AND SUBTITLE Differential Activation of p53 Target Genes in Breast Cancer			5. FUNDING NUMBERS DAMD17-99-1-9308	
6. AUTHOR(S) Edward Thornborrow, MA James Manfredi, Ph.D.			8. PERFORMING ORGANIZATION REPORT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Mount Sinai School of Medicine New York, New York 10029 E-MAIL: et@doc.mssm.edu				
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Distribution authorized to U.S. Government agencies only (proprietary information, May 00). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) A significant percentage of breast tumors have been shown to be resistant to apoptotic stimuli. This resistance has been correlated with a decreased expression of the proapoptotic protein bax. A major regulator of bax expression is the tumor suppressor p53. When compared to alternate target genes data suggest that the bax gene is differentially regulated by p53. Our goal is to understand the mechanism by which p53 selectively regulates the transcription of the pro-apoptotic bax gene. We have identified the minimal p53 responsive element in the human bax promoter, and have found it to be unique in that it consists of three p53 half-sites instead of the typical two. In addition, this minimal element appears to bind with sequence specificity to at least two factors in addition to p53. One of these factors is the transcription factor Sp1 which appears to contribute significantly to the basal activity of the bax promoter. The other, Factor X (as yet unidentified) binds to sequences within the p53 response element that confer transcriptional repression in the absence of p53, suggesting that Factor X may possess potent oncogenic properties through its ability to effectively compete p53 for binding to the bax promoter.				
14. SUBJECT TERMS Breast Cancer			15. NUMBER OF PAGES 13	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Limited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

___ Where copyrighted material is quoted, permission has been obtained to use such material.

___ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

___ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

N/A In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

X For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

 5-28-00

Table of Contents

Cover.....	
SF 298.....	
Foreword.....	
Introduction.....	6
Body.....	7
Key Research Accomplishments.....	10
Reportable Outcomes.....	10
Conclusions.....	
References.....	
Appendices.....	10

Differential Activation of p53 Target Genes in Breast Cancer

Introduction:

In the past decade, there have been great advances in the field of breast cancer. These advances largely have been in the fields of education and early detection. Unfortunately, however, the treatment of breast cancer continues to be problematic in that a significant proportion of tumors are resistant to chemotherapy. Evidence suggests that this resistance is due to a defect in the normal programmed cell death or apoptotic pathway. A complete understanding of the apoptotic mechanism, therefore, is essential for designing the most therapeutic regimen for the treatment of breast cancer. The protein bax is a key regulator of the apoptotic process, and low levels of this protein correlate with a decreased response to treatment and a decreased survival period in breast cancer patients. A major regulator of bax transcription is the tumor suppressor protein p53, and the work I am conducting in this fellowship addresses the transcriptional regulation of the *bax* gene by p53. As such, I hope to understand the mechanism by which bax levels are reduced in breast tumor cells, and then to use this information to elevate the level of activation of the *bax* gene, causing breast tumors to become sensitive to apoptotic stimuli like chemotherapy. I believe that completion of the work proposed in this fellowship will enhance our understanding of both the origins of breast cancer and how tumors respond to treatment. In addition, I believe this work will identify novel targets for therapeutic intervention in breast tumors that are otherwise resistant to current treatment.

Differential Activation of p53 Target Genes in Breast Cancer

Body:

A significant percentage of breast tumors have been shown to be resistant to apoptotic stimuli such as chemotherapeutic drugs. This resistance has been correlated with a decreased expression of the proapoptotic protein *bax*. Low *bax* levels have been associated with a decreased treatment response and a shorter survival time in women with metastatic breast adenocarcinoma. In addition, overexpression of *bax* in tumor cell lines sensitizes the cells to drug-induced apoptosis. A major regulator of *bax* expression is the tumor suppressor p53. p53 is a well-characterized transcription factor that can bind DNA in a sequence specific manner and activate the transcription of particular genes, including *bax*. When compared to alternate p53 targets such as the cyclin dependent kinase inhibitor *p21*, several lines of evidence suggest that the *bax* gene is differentially regulated by p53. Preliminary data presented in the fellowship application demonstrated that the breast carcinoma MCF-7 and MDA-MB-453 cell lines both exhibited a defect in the ability of wild-type p53 to activate transcription through both the intact *bax* promoter as well as the p53 response element in isolation from the promoter. This defect was specific for *bax* as p53 was capable of activating transcription of other p53-dependent target genes, such as the cyclin-dependent kinase inhibitor *p21*. The goal of the work being conducted in this fellowship is to understand the molecular mechanism by which wild-type p53 selectively fails to activate the transcription of the pro-apoptotic *bax* gene.

Work on this project began by identifying the minimal sequence within the *bax* promoter required to mediate p53-dependent transactivation. In contrast to other well characterized p53 response elements, which consist of two copies (half-sites) of sequences that closely resemble the palendromic decamer 5'-RRRCWWGYYY-3' (where R is a purine, Y is a pyrimidine, and W is an adenine or threonine) separated from each other by 0-13 bases, the minimal element from the *bax* promoter consists of three copies of this sequence, or three half-sites. Using this minimal sequence as a probe in electrophoretic mobility shift assays (EMSAs) with nuclear extract from MDA-MB-453 cells, a nuclear factor was identified that demonstrates marked sequence specificity for this p53 response element. This factor, referred to as BBF (Bax Binding Factor) in the original fellowship application, is specific for the p53-response element of *bax* as it fails to bind other well-characterized p53-response elements, including that of the cyclin-dependent kinase inhibitor *p21*. Five tasks were proposed in the original fellowship application to address the biological role of this binding factor in both breast tumor formation and resistance to treatment: 1) Identify additional wild-type p53 breast cancer cell lines that fail to activate transcription of the *bax* gene and fail to undergo p53-dependent apoptosis in response to DNA damage; 2) Explore a possible correlation between BBF levels and a cell line's ability to activate transcription of the *bax* gene and to undergo p53-dependent apoptosis; 3) Purify and clone BBF; 4) Determine the relevance of BBF to the apoptotic response in relevant breast cell model

Differential Activation of p53 Target Genes in Breast Cancer

systems; 5) Examine the potential correlation between BBF levels, *bax* levels, and p53 status in breast tumor biopsy samples as compared to normal mammary epithelium.

Mutational analysis of the p53 response element from the *bax* promoter has demonstrated that the BBF binding site is confined to the p53 half-site most proximal to the start site of transcription. This half-site consists of the sequence 5'-GGGCGTGGGC-3'. This sequence closely resembles the consensus DNA-binding sequence for the Sp1 transcription factor. EMSA analysis with antibodies directed against Sp1 demonstrated that in fact BBF is Sp1. With the fortuitous identification of BBF as Sp1, Task #3 has been successfully completed ahead of schedule. Subsequent to the identification of BBF as Sp1, we have found that Sp1 has a very high affinity for the p53 response element from the *bax* promoter, comparable to its affinity for its consensus DNA-binding sequence. Further, transfection assays in the Sp1 deficient *Drosophila* SL-2 cell line have demonstrated that Sp1 is capable of activating transcription through the p53 response element of the *bax* promoter in a sequence specific manner. Studies are currently underway in SL-2 cells to explore a potential transcriptional interaction between Sp1 and p53 on the *bax* promoter. These studies, however, may be complicated by interference from the recently identified *drosophila* homolog to the p53 protein. An additional approach, therefore, is being pursued which involves using an antisense-Sp1 expression vector to deplete Sp1 from various cell lines and subsequently assay the ability of p53 to activate *bax* expression and to trigger apoptosis (Task #4).

In addition to identifying BBF as Sp1, the mutational analysis of the p53 response element from the *bax* promoter allowed for the identification of an additional factor (Factor X) which appears to mediate sequence specific repression of transcription through the two distal p53 half-sites. In transient transfection assays, deletion of these half sites, leaving the Sp1 binding site intact, leads to an approximate 45-fold increase in basal levels of expression. In addition to identifying repressing sequences, these data also suggest that there is a significant activating role for the GC-rich sequence that binds Sp1. Insertion of this GC-rich sequence upstream of the adenovirus E1b-minimal promoter confers a 45-fold increase in basal expression levels when compared to comparable vectors not containing this sequence. Together, these data have caused us to propose a new model for the p53-dependent transcriptional activation of the *bax* gene. In the absence of p53, we propose that the *bax* promoter is repressed by Factor X, functioning through the two distal p53 half-sites. When p53 levels are elevated, as in response to DNA damage, it effectively competes with Factor X for binding to its response element, displacing it. In the absence of the repressor, p53 and Sp1 may cooperate to drive transcription of the *bax* gene, leading to apoptosis. If this model holds true, Factor X, with its ability to inhibit the p53-dependent activation of *bax*, may represent a protein with significant oncogenic properties. We, therefore, are vigorously attempting to address the biological significance of this factor in both breast tumor formation and resistance to treatment, using the same set of tasks originally

Differential Activation of p53 Target Genes in Breast Cancer

developed for BBF/Sp1. At the same time, we are continuing to pursue the significance of Sp1 in its own right.

In addition to the above research accomplishments, significant training accomplishments have been made. To be properly prepared for a successful career in the battle against breast cancer one should be familiar with both the history of research as well as the most current techniques used in the field. I believe that the work I am conducting is so intimately connected to both the origins and the treatment of breast cancer that it will provide me with the broad foundation of knowledge and technical skill that will allow me to continually identify important clinical aspects of breast cancer that can benefit from further scientific research. As an M.D./Ph.D. student at the Mount Sinai School of Medicine I am receiving specialized training that will allow me to traverse both the clinical and basic science worlds. The work I am conducting in the laboratory is an essential compliment to my clinical training that will continue to provide me with the skills to decrease the gap between benchtop discoveries and bedside cures. The experience of designing my research project and scrutinizing my experimental data is helping me to develop the analytical skills and experience necessary for a productive future battling breast cancer.

Differential Activation of p53 Target Genes in Breast Cancer

Appendices:

Key Research Accomplishments:

- Identified minimal p53 responsive element in the human *bax* promoter.
 - Found the response element to be unique in that it consists of three p53 half-sites instead of the typical two.
- Demonstrated that Sp1 binds with sequence specificity to the same region of the *bax* promoter that is required for p53-dependent transcriptional activation.
 - Found that in the absence of surrounding repressing sequences the Sp1-binding sequence contributes significantly to the basal activity of the *bax* promoter.
 - Demonstrated that Sp1 can activate through this sequence in a sequence-specific manner.
- Identified sequences within the p53 response element of the *bax* promoter that confer transcriptional repression in the absence of p53.

Reportable Outcomes:

Edward C. Thornborrow and James J. Manfredi (2000), A high-affinity Sp1 binding site is located within the p53-response element of the human *bax* promoter (Abstract), 10th International p53 Workshop, Monterey, California.

Cited Manuscripts and Abstracts:

Attached as pages 11-13

Poster Session: 2

Poster: 58

Edward C. Thornborrow

A high-affinity Sp1 binding site is located within the p53-response element of the human *bax* promoter.

Edward C. Thornborrow and James J. Manfredi. Derald H. Ruttenberg Cancer Center and Department of Biochemistry and Molecular Biology, Mount Sinai School of Medicine, New York, NY.

The tumor Suppressor protein p53 has been shown to mediate transcriptional activation of many of its target genes via a response element containing two consensus half-sites, each half-site consisting of PuPuPuC(A/T)(A/T)GPyPyPy. In contrast, activation by p53 of the element in the human *bax* promoter requires a cooperative interaction between three adjacent half-sites (Thornborrow and Manfredi, 1999, J. Biol. Chem. 274, 33747). The half-site most proximal to the start site of transcription contains the sequence 5'-GGGCGTGGGC-3', which closely resembles the DNA-binding consensus sequence for the transcription factor Sp1. Electrophoretic mobility shift assays (EMSAs) using an oligonucleotide containing the p53-response element derived from the *bax* promoter as radiolabeled probe demonstrated that a factor from nuclear extracts bound to this probe and this DNA-protein complex is supershifted by an anti-Sp1 antibody. Competition experiments using oligonucleotides corresponding to a number of well characterized p53-response elements, including those from the *p21*, *cyclin G*, *IGF-BP3*, *mdm-2*, and *gadd45* genes, demonstrated that the binding of Sp1 to the p53 response element of the *bax* promoter was specific. Further, competition experiments with an oligonucleotide containing the Sp1 DNA-binding consensus sequence showed that the affinity of Sp1 for the p53 response element of *bax* is equal to if not greater than that of Sp1 for its consensus sequence. Deletion of the Sp1 binding site from the *bax* element results in a loss of demonstrable p53-dependent transcriptional activation in luciferase reporter assays. These results suggest that Sp1 and/or other Sp family members with similar DNA-binding characteristics, are important in regulating the p53-dependent transcriptional activation of the human *bax* gene.

Poster Session: 2

Poster: 58

Edward C. Thornborrow

A high-affinity Sp1 binding site is located within the p53-response element of the human *bax* promoter.

Edward C. Thornborrow and James J. Manfredi. Derald H. Ruttenberg Cancer Center and Department of Biochemistry and Molecular Biology, Mount Sinai School of Medicine, New York, NY.

The tumor Suppressor protein p53 has been shown to mediate transcriptional activation of many of its target genes via a response element containing two consensus half-sites, each half-site consisting of PuPuPuC(A/T)(A/T)GPyPyPy. In contrast, activation by p53 of the element in the human *bax* promoter requires a cooperative interaction between three adjacent half-sites (Thornborrow and Manfredi, 1999, J. Biol. Chem. 274, 33747). The half-site most proximal to the start site of transcription contains the sequence 5'-GGGCGTGGGC-3', which closely resembles the DNA-binding consensus sequence for the transcription factor Sp1. Electrophoretic mobility shift assays (EMSAs) using an oligonucleotide containing the p53-response element derived from the *bax* promoter as radiolabeled probe demonstrated that a factor from nuclear extracts bound to this probe and this DNA-protein complex is supershifted by an anti-Sp1 antibody. Competition experiments using oligonucleotides corresponding to a number of well characterized p53-response elements, including those from the *p21*, *cyclin G*, *IGF-BP3*, *mdm-2*, and *gadd45* genes, demonstrated that the binding of Sp1 to the p53 response element of the *bax* promoter was specific. Further, competition experiments with an oligonucleotide containing the Sp1 DNA-binding consensus sequence showed that the affinity of Sp1 for the p53 response element of *bax* is equal to if not greater than that of Sp1 for its consensus sequence. Deletion of the Sp1 binding site from the *bax* element results in a loss of demonstrable p53-dependent transcriptional activation in luciferase reporter assays. These results suggest that Sp1 and/or other Sp family members with similar DNA-binding characteristics, are important in regulating the p53-dependent transcriptional activation of the human *bax* gene.

Poster Session: 2

Poster: 58

Edward C. Thornborrow

A high-affinity Sp1 binding site is located within the p53-response element of the human *bax* promoter.

Edward C. Thornborrow and James J. Manfredi. Derald H. Ruttenberg Cancer Center and Department of Biochemistry and Molecular Biology, Mount Sinai School of Medicine, New York, NY.

The tumor Suppressor protein p53 has been shown to mediate transcriptional activation of many of its target genes via a response element containing two consensus half-sites, each half-site consisting of PuPuPuC(A/T)(A/T)GPyPyPy. In contrast, activation by p53 of the element in the human *bax* promoter requires a cooperative interaction between three adjacent half-sites (Thornborrow and Manfredi, 1999, J. Biol. Chem. 274, 33747). The half-site most proximal to the start site of transcription contains the sequence 5'-GGGCGTGGGC-3', which closely resembles the DNA-binding consensus sequence for the transcription factor Sp1. Electrophoretic mobility shift assays (EMSAs) using an oligonucleotide containing the p53-response element derived from the *bax* promoter as radiolabeled probe demonstrated that a factor from nuclear extracts bound to this probe and this DNA-protein complex is supershifted by an anti-Sp1 antibody. Competition experiments using oligonucleotides corresponding to a number of well characterized p53-response elements, including those from the *p21*, *cyclin G*, *IGF-BP3*, *mdm-2*, and *gadd45* genes, demonstrated that the binding of Sp1 to the p53 response element of the *bax* promoter was specific. Further, competition experiments with an oligonucleotide containing the Sp1 DNA-binding consensus sequence showed that the affinity of Sp1 for the p53 response element of *bax* is equal to if not greater than that of Sp1 for its consensus sequence. Deletion of the Sp1 binding site from the *bax* element results in a loss of demonstrable p53-dependent transcriptional activation in luciferase reporter assays. These results suggest that Sp1 and/or other Sp family members with similar DNA-binding characteristics, are important in regulating the p53-dependent transcriptional activation of the human *bax* gene.



DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MARYLAND 21702-5012

REPLY TO
ATTENTION OF:

MCMR-RMI-S (70-1y)

21 Feb 03

MEMORANDUM FOR Administrator, Defense Technical Information
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,
VA 22060-6218


SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl


PHYLLIS M. RINEHART
Deputy Chief of Staff for
Information Management

ADB263458	ADB282838
ADB282174	ADB233092
ADB270704	ADB263929
ADB282196	ADB282182
ADB264903	ADB257136
ADB268484	ADB282227
ADB282253	ADB282177
ADB282115	ADB263548
ADB263413	ADB246535
ADB269109	ADB282826
ADB282106	ADB282127
ADB262514	ADB271165
ADB282264	ADB282112
ADB256789	ADB255775
ADB251569	ADB265599
ADB258878	ADB282098
ADB282275	ADB232738
ADB270822	ADB243196
ADB282207	ADB257445
ADB257105	ADB267547
ADB281673	ADB277556
ADB254429	ADB239320
ADB282110	ADB253648
ADB262549	ADB282171
ADB268358	ADB233883
ADB257359	ADB257696
ADB265810	ADB232089
ADB282111	ADB240398
ADB273020	ADB261087
ADB282185	ADB249593
ADB266340	ADB264542
ADB262490	ADB282216
ADB266385	ADB261617
ADB282181	ADB269116
ADB262451	
ADB266306	
ADB260298	
ADB269253	
ADB282119	
ADB261755	
ADB257398	
ADB267683	
ADB282231	
ADB234475	
ADB247704	
ADB258112	
ADB267627	